VolitionRX (NYSEAMERICAN:VNRX) posted its quarterly earnings results on Wednesday. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.03, Fidelity Earnings reports.

VolitionRX stock opened at $2.97 on Friday. VolitionRX has a 52 week low of $1.44 and a 52 week high of $3.45.

ILLEGAL ACTIVITY NOTICE: “VolitionRX (VNRX) Issues Quarterly Earnings Results” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2019/03/15/volitionrx-vnrx-issues-quarterly-earnings-results.html.

VolitionRX Company Profile

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Further Reading: What are no-load funds?

Earnings History for VolitionRX (NYSEAMERICAN:VNRX)

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.